Oneness Biotech Co., Ltd. 4743

TPEX · Taiwan · Health Technology

TWD 45.85-1.30 (-2.76%)

Market closed· Oct 1, 2026, 5:30 AM UTC· TWD · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Oneness Biotech Co., Ltd. 4743

TPEX · Taiwan · Health Technology

TWD 45.85-1.30 (-2.76%)

Market closed· Oct 1, 2026, 5:30 AM UTC· TWD · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

-13.82% · 6MFull-screen chart

Open TWD 47.15High TWD 47.25Low TWD 45.65Close TWD 45.85Volume 1.30M

Oct 1, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: TWD 47.15
Day range: TWD 45.65 – TWD 47.25
52-week range: TWD 40.80 – TWD 76.70
Volume: 1.30M
Market cap: TWD 22.61B
P/E (TTM): 351.5
Next earnings date: 2026-11-05
Avg. volume (1Y): 2.52M

Performance

1 week

+4.43%

1 month

+1.40%

3 months

-9.50%

6 months

-13.49%

Year to date

-15.95%

1 year

-31.07%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Pharmaceuticals: Major
Country: Taiwan
Exchange: TPEX
Shares outstanding: 479.50M
ISIN: TW0004743000
Beta: 0.67

Technical view

Below averages

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceSep 29, 2026

Oneness Biotech Advances SNS851 to Phase 1 Multiple-Ascending Dose Evaluation for Obesity-Associated Metabolic Diseases

TAIPEI CITY, Taiwan, September 29, 2026--Oneness Biotech completed the SAD portion of its Phase 1 trial evaluating SNS851 as a potential treatment for obesity-associated metabolic diseases.

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.